Breast Cancer Drug

AstraZeneca's experimental drug disappoints in breast cancer survival trial

The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance

Breast cancer to cause million deaths a year by 2040: Lancet commission

Breast cancer is now the world's most common carcinogenic disease, with the ailment likely to cause a million deaths a year by 2040, , a new Lancet commission has found. Around 7.8 million women were diagnosed with breast cancer in five years till the end of 2020 and about 685,000 women died from the disease the same year, it said. Globally, breast cancer cases will increase from 2.3 million in 2020 to more than 3 million by 2040, with low- and middle-income countries being "disproportionately affected", the commission estimated. By 2040, deaths due to the disease will be a million a year, it added. The Lancet report pointed to "glaring inequities" and suffering from symptoms, despair and financial burden due to breast cancer, which are often "hidden and inadequately addressed". Laying out recommendations for tackling these challenges in breast cancer, the commission suggested better communication between patients and health professionals as a crucial intervention that could impro

Many cancer drugs remain unproven 5 yrs after accelerated approval: Study

The U.S. Food and Drug Administration's accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients' lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years. Five years after the initial accelerated approval, you should have a definitive answer, said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. Thousands of people are getting those drugs. That seems a mistake if we don't know whether they work or not." The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs. It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce

Breast cancer strikes younger Indian women at an alarming rate: Study

A striking 25 per cent of breast cancer cases among Indian women occurred at the age of 39 years or younger

Dr Reddy's acquires trademark rights for Pfizer breast cancer drug

Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv

Breast cancer among men slowly on the rise & usually detected late: Doctors

The disease is now being diagnosed in relatively younger men

Alembic Pharma gets tentative USFDA nod for breast cancer treatment drug

Drug firm Alembic Pharmaceuticals said it has received tentative approval from the US health regulator for Palbociclib capsules, used to treat a certain type of breast cancer

AstraZeneca agrees to pay Japan's Daiichi $6 bn for new cancer drug

The UK drugmaker will pay Japan's Daiichi $1 billion upfront to jointly develop and bring to market a cancer therapy in early clinical tests called DS-1062, the companies said

In a first, WHO approves medicine to make breast cancer treatment cheaper

The trastuzumab drug has shown "high efficacy" in curing early stage breast cancer and in some cases more advanced forms of the disease

Fitness may lower breast cancer risk

Findings offer tantalising new clues into relationship between fitness, exercise and malignancies

New potential breast cancer drug identified

The new molecule, dubbed ERX-11, mimics a peptide, or protein building block